

HETEROCYCLES, Vol. 73, 2007, pp. 743 - 750. © The Japan Institute of Heterocyclic Chemistry
Received, 27th July, 2007, Accepted, 4th October, 2007, Published online, 9th October, 2007. COM-07-S(U)55

SYNTHESIS OF THIOAPLYSINOPSIN ANALOGS DERIVED FROM 5-DIMETHYLAMINOMETHYLIDENE-2-THIOXO-1,3-THIAZOL-4-ONES

Renata Jakše, Uroš Grošelj, Gorazd Soršak, Jurij Svete,* and Branko Stanovnik*

Faculty of Chemistry and Chemical Technology, University of Ljubljana,
Aškerčeva 5, P.O. Box 537, 1000 Ljubljana, Slovenia, e-mail:
Branko.Stanovnik@fkkt.uni-lj.si

Dedicated to the memory of Dr. Ivar Ugi

Abstract – Some new thioaplysinsin analogs **4a-d** were prepared from indole (**3a**) and or 2-methylindole (**3b**) and 5-dimethylaminomethylidene- (**2a-c**) or 5-ethoxymethylidene-2-thioxo-1,3-thiazol-4-ones (**2d**) derived rhodanine derivatives (**1a,b**). Cycloaddition of *N*-phenyl-4-chlorobenzonitrileimine to C=S bond in **4c** and in thioaplysinsin derivatives **6a,b** afforded the corresponding spiro compounds 4,9-diphenyl-2-(4-chlorophenyl)-7-[1-(2-methylindol-3-yl)methylidene]-1,6-dithia-3,4,9-triazaspiro-[4.4]non-2-en-8-one (**5**) and 2-(4-chlorophenyl)-8-[(*Z*)-1-(2-methyl-1*H*-indol-3-yl)methylidene]-4,6-diaryl-1-thia-3,4,6,9-tetraazaspiro[4.4]non-3-en-7-one (**7a,b**).

INTRODUCTION


A large number of indole derivatives substituted at 3 position exhibit various biological activities. The substituents at 3 position in the indole ring are formyl group, carboxymethyl group, a five or six membered heterocyclic ring, such as maleimidyl, imidazolyl, dihydroimidazolyl, oxazolyl, oxadiazinyl, pyrazinyl, pyrimidinyl, and others. Among these indole alkaloids are meridianins, isolated from south atlantic tunicate *Aplium meridianum*,¹ some of them have been described as potent kinase inhibitors,² while others display antitumor activity,³ and dipodazines, a diketopiperazine condensation products derived from dehydrotryptophane and glycine, isolated from *Penicillium dipodomyis* and meat-associated

P. nalgiovese,⁴ and others. Aplysinopsin and its derivatives were isolated from marine sponges *Aplysinopsis reticulata*, *Verongia spengellii*, *Dercitus sp.*, and *Tubastrea sp.*⁵⁻⁸ Some of these compounds display biological activity,⁸ such as specific cytotoxicity for cancer cells⁵ and in affecting neurotransmission.⁹ These findings caused a great interest in their synthesis.¹⁰⁻¹⁵

In the course of our studies on the application of alkyl 3-dimethylaminopropenoates and related enaminones in the synthesis of heterocyclic systems and natural products and their analogs¹⁶⁻¹⁸ we recently focused our attention also on preparation of chiral enaminones available from amino acids.^{16,19-23} In this connection, we already reported on the application of 5-[(dimethylamino)methylidene]imidazolidine-2,4-dione and its 3-methyl derivative as well as on the application of 5-[(dimethylamino)methylidene]-2-thioxoimidazolidin-4-one with an easy exchangeable dimethylamino group as an alternative way of preparing some aryl and heteroaryl aplysinopsin analogues.²⁴⁻²⁸


RESULTS AND DISCUSSION

As a continuation of research in this field we report on the stereoselective preparation of new thioaplysinopsin derivatives. Rhodanine (**1a**) and phenylrhodanine (**1b**) were converted with *N,N*-dimethylformamide dimethyl acetal (DMFDMA), *tert*-butoxybis(dimethylamino)methane (Bredereck's reagent), or triethyl orthoformate to the corresponding dimethylaminomethylidene (**2a-c**) and ethoxymethylidene (**2d**) derivatives. These compounds were then converted with indole (**3a**) and 2-methylindole (**3b**) to novel thioaplysinopsin analogs (**4a-d**). (Schemes 1).



Scheme 1. Reagents and reaction conditions: i for **2a,c**: Bredereck's reagent, DMF, reflux; for **2b**: *N,N*-dimethylformamide dimethyl acetal (DMFDMA), DMF, reflux; for **2d**: triethyl orthoformate, Ac₂O, reflux; ii AcOH, reflux.

Compound **4c** and two other thioaplysinsin derivatives **6a,b**, prepared previously in our laboratory,²⁵ were treated with *N*-phenyl-4-chlorobenzonitrileimine, prepared *in situ* from *N*-phenyl-4-chlorobenzecarbohydrazonic chloride and Et₃N. 1,3-Dipolar cycloaddition took place across at exocyclic C=S double bond in the thiazole or imidazole ring to afford the corresponding spiro products **5** and **7a,b**, respectively. (Scheme 2).



Scheme 2. Reagents and reaction conditions: **i** *N*-phenyl-4-chlorobenzonitrileimine, Et₃N, THF, reflux.

STRUCTURE DETERMINATION

The structures of new compounds were determined on the basis of their MS spectra, elemental analyses for C, H, and N, ¹³C NMR and ¹H NMR spectra. The (*Z*)-configuration around the exocyclic double bond in compounds **2b**, **4b** and **5** was determined by NMR (HMBC technique) on the basis of the magnitude of long-range heteronuclear coupling constant between the proton attached to the double bond and ¹³C of the carbonyl group attached to the double bond ³J_{C-H}.²⁹⁻³⁷ The magnitude of the coupling constant, ³J_{C-H} = 4-6 Hz, indicates the *cis*-relationship between the methine proton and the carbonyl carbon atom and is also in agreement with the literature data.

EXPERIMENTAL

Melting points were taken on a Kofler micro hot stage. The ¹H NMR spectra were obtained on a Bruker

Avance DPX 300 (300 MHz) spectrometer in such solvent as DMSO- d_6 and $CDCl_3$ with TMS as the internal standard, MS spectra on an AutoSpecQ spectrometer, IR spectra on a Perkin-Elmer 1310 infrared spectrophotometer and elemental analyses for C, H and N on a Perkin-Elmer CHN Analyser 2400.

General Procedure for the Preparation of Starting Compounds 2a-d:

To the DMF or acetic acid anhydride solution of rhodanine (**1a**) or phenylrhodanine (**1b**), *N,N*-dimethylformamide dimethyl acetal (DMFDMA), *tert*-butoxybis(dimethylamino)methane (Bredereck's reagent), or triethyl orthoformate was added. The mixture was heated under reflux for several hours, the volatile compounds were evaporated *in vacuo* and precipitate was collected by filtration. The solid residue was crystallised from an appropriate solvent.

5-Dimethylaminomethylidene-2-thioxo-1,3-thiazol-4-one (2a). This compound was prepared from rhodanine (**1a**; 0.40 g, 0.003 mol) and Bredereck's reagent (0.70 g, 0.004 mol) in DMF (8 mL), 3h, 62% yield (0.35g); mp 229-230 °C (from MeCN), 1H NMR (DMSO- d_6) δ : 3.14 (6H, s, NMe_2), 7.54 (1H, s, CH), 12.82 (1H, s, NH). *Anal.* Calcd for $C_6H_8N_2OS_2$: C, 38.28; H, 4.28; N, 14.88. Found: C, 38.30; H, 4.23; N, 14.85.

5-Dimethylaminomethylidene-3-methyl-2-thioxo-1,3-thiazol-4-one (2b). This compound was prepared from rhodanine (**1a**; 0.27 g, 0.002 mol) and DMFDMA (0.60 g, 0.005 mol) in DMF (5 mL), 2h, 91% yield (0.37g); mp 172-173 °C (from DMF). 1H NMR (DMSO- d_6) δ : 3.19 (6H, s, NMe_2), 3.31 (3H, s, NMe), 7.75 (1H, s, CH). *Anal.* Calcd for $C_7H_{10}N_2OS_2$: C, 41.56; H, 4.98; N, 13.85. Found: C, 41.62; H, 4.85; N, 13.89.

5-Dimethylaminomethylidene-3-phenyl-2-thioxo-1,3-thiazol-4-one (2c). This compound was prepared from phenylrhodanine (**1b**; 1.04 g, 0.005 mol) and Bredereck's reagent (1.4 g, 0.008 mol) in toluene (10 mL), 2h, 61% yield (0.81g); mp 193-194 °C, 1H NMR (DMSO- d_6) δ : 3.22 (s, 6H, NMe_2), 7.21-7.25 (m, 2H, Ph), 7.44-7.55 (m, 3H, Ph), 7.73 (s, 1H, CH). ^{13}C NMR (DMSO- d_6) δ : 88.3, 129.6, 129.7, 130.0, 137.2, 147.6, 167.6, 191.4. *Anal.* Calcd for $C_{12}H_{12}N_2OS_2$: C, 54.52; H, 4.58; N, 10.60. Found: C, 54.39; H, 4.42; N, 10.62.

5-Ethoxymethylidene-2-thioxo-1,3-thiazol-4-one (2d). This compound was prepared from rhodanine (**1a**; 1.33 g, 0.010 mol) and triethyl orthoformate (1.70 g, 0.011 mol) in acetic anhydride (20 mL), 3h, 60% yield (1.13 g); mp 144-145 °C (from a mixture of EtOH and *n*-heptane). 1H NMR (DMSO- d_6) δ : 1.28 (3H, t, $J_{CH_2CH_3} = 7.1$ Hz, OCH_2CH_3), 4.33 (2H, q, $J_{CH_2CH_3} = 7.1$ Hz, OCH_2CH_3), 7.82 (1H, s, CH), 13.24 (1H, s,

NH). *Anal.* Calcd for $C_6H_7NO_2S_2$: C, 38.08; H, 3.73; N, 7.40. Found: C, 37.95; H, 3.49; N, 7.61.

General Procedure for the Preparation of Compounds 4a-d:

Compounds **2a-d** were dissolved in glacial acetic acid (8 mL). To the solution the corresponding indole derivative **3a** or **3b** was added and the mixture was heated under reflux for several hours. The volatile compounds were evaporated *in vacuo* and the precipitate was collected by filtration. The solid residue was crystallised from an appropriate solvent.

(Z)-5-[(2-Methylindol-3-yl)methylidene]-2-thioxo-1,3-thiazol-4-one (4a). This compound was prepared from compound **2a** (0.37 g, 0.002 mol) and 2-methylindole (**3b**; 0.28 g, 0.002 mol), 6h, 40% yield (0.22 g); mp 314 °C (from a mixture of MeCN and DMF (decomp)). 1H NMR (DMSO- d_6) δ : 2.51 (3H, s, Me), 7.18-7.21 (2H, m, H_5 , H_6), 7.39-7.41 (1H, m, H_4), 7.43-7.83 (1H, m, H_7), 8.84 (1H, s, $H-C(5')$), 12.16 (1H, s, NH), 13.47 (1H, s, NH). *Anal.* Calcd for $C_{13}H_{10}N_2OS_2$: C, 56.91; H, 3.67; N, 10.21. Found: C, 56.73; H, 3.52; N, 9.94.

(Z)-5-[(2-Methylindol-3-yl)methylidene]-3-methyl-2-thioxo-1,3-thiazol-4-one (4b). This compound was prepared from compound **2b** (0.40 g, 0.002 mol) and 2-methylindole (**3b**; 0.28 g, 0.002 mol), 8h, 75% yield (0.43 g), mp 290-291 °C (from AcOH). 1H NMR (DMSO- d_6) δ : 2.58 (3H, s, 2-Me), 3.42 (3H, s, NMe), 7.22 (2H, dd, $J_{H4-H6} = J_{H7-H5} = 3.0$ Hz, $J_{H4-H5} = J_{H7-H6} = 6.0$ Hz, H_5 , H_6), 7.43 (1H, dd, $J_{H4-H6} = 3.0$ Hz, $J_{H4-H5} = 6.0$ Hz, H_4), 7.85 (1H, dd, $J_{H7-H5} = 3.0$ Hz, $J_{H7-H6} = 6.0$ Hz, H_7), 8.00 (1H, s, $H-C(5')$), 12.24 (1H, s, NH). *Anal.* Calcd for $C_{14}H_{12}N_2OS_2 \cdot 1/2 H_2O$: C, 56.55; H, 4.40; N, 9.42. Found: C, 56.57; H, 4.00; N, 9.16.

(Z)-5-[(2-Methylindol-3-yl)methylidene]-3-phenyl-2-thioxo-1,3-thiazol-4-one (4c). This compound was prepared from compound **2c** (0.132 g, 0.0005 mol) and 2-methylindole (**3b**; 0.06 g, 0.0005 mol), 1.5h, 50% yield (0.09 g); mp 314-315 °C (from acetone). IR 3300, 1670, 1550 cm^{-1} . 1H NMR (DMSO- d_6) δ : 2.59 (s, 3H, Me), 7.21-7.27 (m, 2H, Ph), 7.38-7.46 (m, 3H, Ph), 7.51-7.60 (m, 3H, 4-H, 5-H, 6-H), 7.88-7.93 (m, 1H, 7-H), 8.01 (s, 1H, CH), 12.25 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ : 13.3, 109.2, 112.9, 115.0, 120.3, 122.2, 123.6, 125.6, 129.6, 130.1, 136.7, 137.1, 146.3, 167.8, 193.4. *Anal.* Calcd for $C_{19}H_{14}N_2OS_2$: C, 65.12; H, 4.03; N, 7.99. Found: C, 65.10; H, 3.95; N, 7.72.

(Z)-5-[(Indol-3-yl)methylidene]-3-methyl-2-thioxo-1,3-thiazol-4-one (4d). This compound was prepared from compound **2d** (0.38 g, 0.002 mol) and indole (**3a**; 0.23 g, 0.002 mol), 4.5h, 49% yield (0.27 g); mp 286 °C (from AcOH). 1H NMR (DMSO- d_6) δ : 3.36 (3H, s, NMe), 7.20-7.30 (2H, m, H_5 , H_6),

7.51-7.54 (1H, m, H₄), 7.90-7.98 (2H, m, H₇, H₂), 8.10 (1H, s, *H*-C(5')), 12.35 (1H, s, NH). *Anal.* Calcd for C₁₃H₁₀N₂OS₂: C, 56.91; H, 3.67; N, 10.21. Found: C, 57.01; H, 3.74; N, 10.25.

General Procedure for the Preparation of Compounds 5, 7a,b.

To the THF solution of thioaplysinopsin derivative and *N*-phenyl-4-chlorobenzenecarbohydrazonic chloride, and Et₃N (2 mL) was added. The mixture was heated for 80 min. under reflux, the volatile compounds were evaporated *in vacuo* and the precipitate was collected by filtration. Solid residue was purified by column chromatography (silica gel 60 (Fluka) and toluene/Et₂O = 4/1).

4,9-Diphenyl-2-(4-chlorophenyl)-7-[(*Z*)-1-(2-methylindol-3-yl)methylidene]-1,6-dithia-3,4,9-triaza-spiro[4.4]non-2-en-8-one (5). This compound was prepared from compound **4c** (0.07 g, 0.0002 mol) and *N*-phenyl-4-chlorobenzenecarbohydrazonic chloride (0.06 g, 0.0002 mol), 65% yield (0.07 g); mp 243-244 °C. MS 579 (M⁺). IR 3280, 1740, 1600 cm⁻¹. ¹H NMR (DMSO-*d*₆) δ: 2.46 (s, 3H, Me), 6.97-7.02 (m, 1H, Ar), 7.07-7.19 (m, 2H, Ar), 7.22-7.25 (m, 2H, Ar), 7.33-7.49 (m, 13H, Ar), 7.94 (s, 1H, 7'-H), 11.74 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆) δ: 13.3, 103.9, 108.0, 118.7, 118.8, 120.6, 123.7, 124.4, 126.2, 128.3, 129.4, 130.0, 130.4, 135.5, 136.0, 136.6, 140.6, 141.7, 165.0. *Anal.* Calcd for C₃₂H₂₃N₄OS₂Cl: C, 66.37; H, 4.00; N, 9.67. Found: C, 66.59; H, 3.91; N, 9.52.

2-(4-Chlorophenyl)-8-[(*Z*)-1-(2-methyl-1*H*-indol-3-yl)methylidene]-4,6-diphenyl-1-thia-3,4,6,9-tetraazaspiro[4.4]non-3-en-7-one (7a). This compound was prepared from 5-[(2-methylindol-3-yl)methylidene]-3-phenyl-2-thiooxoimidazolidin-4-one (**6a**; 0.333 g, 0.001 mol) and *N*-phenyl-4-chlorobenzenecarbohydrazonic chloride (0.265 g, 0.001 mol), 90% yield (0.46 g); mp 234-235 °C. MS 562 (M⁺). IR 1654, 1610, 1600 cm⁻¹. ¹H NMR (DMSO-*d*₆) δ: 2.54 (3H, s, CH₃), 6.93-7.10 (3H, m, *H*-C(4'), *H*-C(6'), *H*-C(5')), 6.93-7.10 (3H, m, *H*-C(4'), *H*-C(6'), *H*-C(5')), 6.99-7.12 (2H, m, *H*-C(6'), *H*-C(5')), 7.17 (1H, d, *J* = 7.9 Hz, *H*-C(7')), 7.37 (1H, d, *J* = 7.9 Hz, *H*-C(4')), 7.52 (1H, s, *H*-C(2')), 7.77 (1H, d, *J* = 7.9 Hz, *H*-C(7')), 7.63 – 7.27 (14H, m, 2Ph and 4-chlorophenyl), 7.99 (2H, d, *J* = 8.7 Hz, H_{ortho}), 8.16 (1H, s, NH), 8.82 (1H, s, NH). ¹³C NMR (DMSO-*d*₆) δ: 13.2, 108.0, 111.7, 115.2, 119.8, 121.2, 121.7, 122.0, 124.4, 124.5, 126.1, 127.8, 128.1, 129.1, 129.5, 129.7, 130.1, 136.2, 136.6, 138.6, 139.5, 139.6, 140.2, 147.6, 157.6, 163.9. *Anal.* Calcd for C₃₂H₂₄N₅OSCl: C, 68.38; H, 4.30; N, 12.46. Found: C, 68.60; H, 4.06; N, 12.24.

2-(4-Chlorophenyl)-8-[(*Z*)-1-(2-methyl-1*H*-indol-3-yl)methylidene]-4-phenyl-6-(4-methylphenyl)-1-thia-3,4,6,9-tetraazaspiro[4.4]non-3-en-7-one (7b). This compound was prepared from 5-[(2-methylindol-3-yl)methylidene]-3-(4-methylphenyl)-2-thiooxoimidazolidin-4-one (**6b**; 0.103 g, 0.0003 mol) and

N-phenyl- 4-chlorobenzenecarbohydrazonic chloride (0.080 g, 0.0003 mol), 85% yield (0.15 g); mp 250-251 °C. MS 576 (M^+). IR 1654, 1612 cm^{-1} . ^1H NMR ($\text{DMSO-}d_6$) δ : 2.31 (3H, s, CH_3), 2.55 (3H, s, CH_3), 6.92-7.62 (15H, m, $H\text{-C}(4')$, $H\text{-C}(6')$, $H\text{-C}(5')$, $H\text{-C}(5')$, 5H Ph, 4H 4-chlorophenyl, 2H 4-methylphenyl), 7.99 (2H, d, $J = 8.3$ z, H_{ortho}), 8.10 (1H, s, NH), 8.75 (1H, s, NH). ^{13}C NMR ($\text{DMSO-}d_6$) δ : 13.2, 21.4, 67.9, 108.0, 111.7, 115.0, 119.7, 121.2, 121.6, 124.4, 126.1, 127.7, 128.2, 129.1, 129.5, 129.7, 129.9, 130.1, 133.4, 136.2, 136.5, 137.1, 138.7, 139.4, 140.2, 157.5, 163.7. *Anal.* Calcd for $\text{C}_{33}\text{H}_{26}\text{N}_5\text{OSCl}$: C, 68.80; H, 4.55; N, 12.16. Found: C, 68.87; H, 4.35; N, 11.83.

ACKNOWLEDGEMENTS

The financial support from the *Slovenian Research Agency*, Slovenia through grants P0-0502-0103, P1-0179, and J1-6689-0103-04 is gratefully acknowledged. Financial support by the pharmaceutical companies *LEK-SANDOZ*, Ljubljana, and *KRKA*, Novo mesto, is fully appreciated

REFERENCES

1. L. H. Franco, E. B. K. Joff , L. Puricelli, M. Tatian, A. M. Seldes, and J. A. Palermo, *J. Nat. Prod.*, 1998, **61**, 1130.
2. M. Gompel, M. Leost, E. B. K. Joff , L. Puricelli, L. H. Franco, J. Palermo, and L. Meijer, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 1703.
3. M. A. A. Radwan and M. El-Sherbiny, *Bioorg. Med. Chem.*, 2007, **14**, 1206.
4. D. S rensen, T. Larsen Ostenfeld, C. Christophersen, P. Nielsen Halfdan, and U. Anthoni, *Phytochemistry*, 1999, **51**, 1181.
5. K. H. Hollenbeak and F. J. Schmitz, *Lloydia*, 1977, **10**, 479.
6. a) P. Djura and D. J. Faulkner, *J. Org. Chem.*, 1980, **45**, 735. b) S. Aoki, Y. Ye, K. Higuchi, A. Takashima, Y. Tanaka, I. Kitagawa, and M. Kobayashi, *Chem. Pharm. Bull.*, 2001, **49**, 1372.
7. G. Guella, I. Mancini, H. Zibrowius, and F. Pietra, *Helv. Chim. Acta*, 1988, **71**, 773.
8. G. Guella, I. Mancini, H. Zibrowius, and F. Pietra, *Helv. Chim. Acta*, 1989, **72**, 1444.
9. J. T. Baker and R. J. Wells in *Natural Products as Medicinal Agents*, ed. by J. T. Beal and Reinhardt, Hippokrates Verlag, Stuttgart, 1981, pp. 299-303.
10. A. Dalkafouki, J. Ardisson, N. Kunesch, L. Lacombe, and J. E. Poisson, *Tetrahedron Lett.*, 1991, **39**, 5325.
11. P. Molina and M. J. Vilaplana, *Chem. Rev.*, 1994, **94**, 1197.
12. P. Molina, P. Almendros, and P. M. Fresneda, *Tetrahedron*, 1994, **50**, 2241.
13. J. M. Chezal, G. Delmas, S. Mavel, H. Elakmaoui, J. Metin, A. Diez, Y. Blache, A. Gueiffier, M. Rubiralta, J. C. Teulade, and O. Chavignon, *J. Org. Chem.*, 1997, **62**, 4085.

14. G. Delmas, P. Deplat, J. M. Chezal, O. Chavignon, A. Gueiffier, Y. Blache, J. L. Chabard, G. Dauphin, and J. C. Teulade, *Heterocycles*, 1996, **43**, 1229.
15. O. Chavignon, J. C. Teulade, D. Roche, M. Madesclaire, Y. Blache, A. Gueiffier, J. L. Chabard, and G. Dauphin, *J. Org. Chem.*, 1994, **59**, 6413 .
16. B. Stanovnik and J. Svete, *Chem. Rev.*, 2004, **104**, 2433.
17. B. Stanovnik and J. Svete, *Synlett*, 2000, 1077.
18. B. Stanovnik and J. Svete, "Alkyl 3-(Dimethylamino)propenoates and Related Compounds as Useful Building Blocks in the Synthesis of Heterocyclic Systems Approaches Towards the Synthesis of Natural Products and their Close Analogs" in "Targets in Heterocyclic Systems. Chemistry and Properties", Vol. **4**, ur. O. A. Attanasi, D. Spinelli, Società Chimica Italiana, Roma 2000, pp. 105–137.
19. S. Pirc, D. Bevk, R. Jakše, S. Rečnik, L. Golič, A. Golobič, A. Meden, B. Stanovnik, and J. Svete, *Synthesis*, 2005, 2969.
20. S. Pirc, D. Bevk, A. Golobič, J. Svete, and B. Stanovnik, *Helv. Chim. Acta*, 2006, **89**, 30.
21. U. Uršič, D. Bevk, S. Pirc, L. Pezdirc, B. Stanovnik, and J. Svete, *Synthesis*, 2006, 2376.
22. J. Waggoner, D. Bevk, A. Meden, J. Svete, and B. Stanovnik, *Helv. Chim. Acta*, 2006, **89**, 240.
23. Časar, D. Bevk, J. Svete, and B. Stanovnik, *Tetraahedron*, 2005, **61**, 7508.
24. L. Selič, R. Jakše, K. Lampič, L. Golič, S. Golič-Grdadolnik, and B. Stanovnik, *Helv. Chim. Acta*, 2000, **83**, 2802.
25. R. Jakše, S. Rečnik, J. Svete, A. Golobič, L. Golič, and B. Stanovnik, *Tetrahedron*, 2001, **57**, 8395.
26. L. Selič and B. Stanovnik, *Tetrahedron*, 2001, **57**, 3159.
27. L. Selič, S. Rečnik, and B. Stanovnik, *Heterocycles*, 2002, **58**, 577.
28. B. Stanovnik and J. Svete, *Mini-Rev. Org. Chem.*, 2005, **2**, 211.
29. H. Seki, T. Tokunaga, H. Utsumi, and K. Yamaguchi, *Tetrahedron*, 2000, **56**, 2935.
30. W. Willker and D. Leibfritz, *Magn. Reson. Chem.*, 1995, **33**, 632.
31. P. Fischer, E. Schweizer, J. Langner, and U. Schmidt, *Magn. Reson. Chem.*, 1994, **32**, 567.
32. K. Ding, *Magn. Reson. Chem.*, 2000, **38**, 321.
33. T. Tokunaga, H. Seki, S. Yasuike, M. Ikoma, J. Kurita, and K. Yamaguchi, *Tetrahedron Lett.*, 2000, **41**, 1031.
34. E. Ősz, L. Szilágyi, and J. Marton, *J. Mol. Struct.*, 1998, **442**, 267.
35. S. Golič Grdadolnik, and B. Stanovnik, *Magn. Reson. Chem.*, 1997, **35**, 482.
36. T. Ando, N. Koseki, R. F. Toia, and J. E. Casida, *Magn. Reson. Chem.*, 1993, **31**, 90.
37. J. J. Titman, J. Foote, J. Jarvis, J. Keeler, and D. Neuhaus, *J. Chem. Soc., Chem. Commun.*, 1991, 419.